Jonathan Cheng, MD Merck – Vice President Clinical Research discusses KEYTRUDA Is the First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients Approval Received Less Than One Month Following Submission of sBLA Application Based on Results of KEYNOTE-177
Jonathan Cheng, MD @Merck #colorectalcancer KEYTRUDA Is the First Single-Agent, Anti-PD-1 Therapy Approved for the First-Line Treatment of These Patients Approval Received Less Than One M…
